Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Kymera Therapeutics, Inc. (KYMR) since 2021 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Kymera Therapeutics, Inc.. (See page 1 of this report.) Table 2 shows the detailed insider transactions. This company's CIK number is 1815442.
Total stock buying since 2021: $284,892,392.
Total stock sales since 2021: $270,271,684.
Total stock option exercises since 2021: $13,461,626.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2026 | 0 | $0 | 391,234 | $33,127,071 | 258,595 | $6,129,642 |
| 2025 | 2,978,480 | $215,297,266 | 891,185 | $62,678,983 | 672,656 | $3,248,952 |
| 2024 | 0 | $0 | 1,458,542 | $58,840,761 | 197,423 | $972,621 |
| 2023 | 414,105 | $5,301,258 | 3,382 | $105,303 | 42,000 | $87,360 |
| 2022 | 1,498,127 | $38,718,066 | 1,080,436 | $34,075,954 | 252,732 | $517,980 |
| 2021 | 544,166 | $25,575,802 | 1,416,229 | $81,443,612 | 456,373 | $2,505,071 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2022-10-31 | Booth Bruce (Director) | Sale | 120,622 | 30.23 | 3,646,403 |
| 2022-10-28 | Atlas Venture Associates Opportunity I, Llc (10% Owner) | Sale | 91,050 | 30.00 | 2,731,500 |
| 2022-10-28 | Booth Bruce (Director) | Sale | 91,050 | 30.00 | 2,731,500 |
| 2022-10-21 | Jacobs Bruce N. (Chief Financial Officer) | Option Ex | 10,000 | 2.08 | 20,800 |
| 2022-10-17 | Mainolfi Nello (Chief Executive Officer) | Option Ex | 59,732 | 2.08 | 124,242 |
| 2022-10-17 | Jacobs Bruce N. (Chief Financial Officer) | Option Ex | 10,000 | 2.08 | 20,800 |
| 2022-08-22 | Lampert Mark N | Buy | 545,525 | 26.00 | 14,183,650 |
| 2022-05-27 | Lampert Mark N | Buy | 65,369 | 14.78 | 966,349 |
| 2022-05-26 | Lampert Mark N | Buy | 224,057 | 14.21 | 3,184,074 |
| 2022-05-20 | Lampert Mark N | Buy | 10,100 | 14.00 | 141,389 |
| 2022-05-06 | Lampert Mark N | Buy | 100,000 | 19.25 | 1,925,500 |
| 2022-05-05 | Lampert Mark N | Buy | 150,000 | 19.60 | 2,939,850 |
| 2022-05-04 | Gollob Jared (Chief Medical Officer) | Option Ex | 20,000 | 1.70 | 33,900 |
| 2022-05-03 | Mainolfi Nello (Chief Executive Officer) | Option Ex | 20,000 | 2.08 | 41,600 |
| 2022-05-03 | Jacobs Bruce N. (Chief Financial Officer) | Option Ex | 20,000 | 2.08 | 41,600 |
| 2022-01-31 | Lampert Mark N | Buy | 34,408 | 40.70 | 1,400,405 |
| 2022-01-27 | Lampert Mark N | Buy | 95,901 | 38.33 | 3,676,077 |
| 2022-01-24 | Lampert Mark N | Buy | 272,767 | 37.76 | 10,300,772 |
| 2022-01-14 | Mainolfi Nello (Chief Executive Officer) | Option Ex | 10,000 | 2.08 | 20,800 |
| 2022-01-14 | Jacobs Bruce N. (Chief Financial Officer) | Option Ex | 10,000 | 2.08 | 20,800 |
| 2022-01-12 | Mainolfi Nello (Chief Executive Officer) | Sale | 8,612 | 52.64 | 453,352 |
| 2022-01-12 | Mainolfi Nello (Chief Executive Officer) | Option Ex | 8,612 | 2.08 | 17,912 |
| 2022-01-12 | Jacobs Bruce N. (Chief Financial Officer) | Sale | 15,000 | 52.20 | 783,060 |
| 2022-01-12 | Jacobs Bruce N. (Chief Financial Officer) | Option Ex | 15,000 | 2.08 | 31,200 |
| 2022-01-11 | Mainolfi Nello (Chief Executive Officer) | Sale | 16,923 | 54.38 | 920,340 |
| 2022-01-11 | Mainolfi Nello (Chief Executive Officer) | Option Ex | 16,923 | 2.08 | 35,199 |
| 2022-01-10 | Mainolfi Nello (Chief Executive Officer) | Sale | 22,465 | 53.80 | 1,208,594 |
| 2022-01-10 | Mainolfi Nello (Chief Executive Officer) | Option Ex | 22,465 | 2.08 | 46,727 |
| 2021-12-16 | Mainolfi Nello (Chief Executive Officer) | Option Ex | 8,000 | 2.08 | 16,640 |
| 2021-12-03 | Jacobs Bruce N. (Chief Financial Officer) | Sale | 10,000 | 54.23 | 542,320 |
| 2021-12-03 | Jacobs Bruce N. (Chief Financial Officer) | Option Ex | 10,000 | 2.08 | 20,800 |
| 2021-11-23 | Jacobs Bruce N. (Chief Financial Officer) | Option Ex | 10,000 | 2.08 | 20,800 |
| 2021-11-02 | Gollob Jared (Chief Medical Officer) | Sale | 14,996 | 63.58 | 953,385 |
| 2021-11-02 | Gollob Jared (Chief Medical Officer) | Option Ex | 14,996 | 2.08 | 31,191 |
| 2021-11-01 | Gollob Jared (Chief Medical Officer) | Sale | 42,497 | 61.85 | 2,628,524 |
| 2021-11-01 | Gollob Jared (Chief Medical Officer) | Option Ex | 24,607 | 1.70 | 41,708 |
| 2021-10-11 | Mainolfi Nello (Chief Executive Officer) | Sale | 6,456 | 54.04 | 348,875 |
| 2021-10-11 | Mainolfi Nello (Chief Executive Officer) | Option Ex | 6,456 | 2.08 | 13,428 |
| 2021-10-08 | Mainolfi Nello (Chief Executive Officer) | Sale | 41,544 | 58.52 | 2,431,279 |
| 2021-10-08 | Mainolfi Nello (Chief Executive Officer) | Option Ex | 41,544 | 2.08 | 86,411 |
| 2021-09-03 | Jacobs Bruce N. (Chief Financial Officer) | Sale | 10,000 | 60.27 | 602,740 |
| 2021-09-03 | Jacobs Bruce N. (Chief Financial Officer) | Option Ex | 10,000 | 2.08 | 20,800 |
| 2021-08-27 | Chesworth Richard (Chief Scientific Officer) | Sale | 33,779 | 60.12 | 2,030,861 |
| 2021-08-27 | Chesworth Richard (Chief Scientific Officer) | Option Ex | 33,779 | 20.00 | 675,580 |
| 2021-08-19 | Mainolfi Nello (Chief Executive Officer) | Option Ex | 12,000 | 2.08 | 24,960 |
| 2021-08-17 | Chesworth Richard (Chief Scientific Officer) | Sale | 54,000 | 51.01 | 2,754,648 |
| 2021-08-17 | Chesworth Richard (Chief Scientific Officer) | Option Ex | 54,000 | 20.00 | 1,080,000 |
| 2021-08-11 | Atlas Venture Associates X, Llc (10% Owner) | Sale | 242,133 | 61.00 | 14,770,113 |
| 2021-08-11 | Booth Bruce (Director) | Sale | 242,133 | 61.00 | 14,770,113 |
| 2021-08-04 | Mainolfi Nello (Chief Executive Officer) | Sale | 1,037 | 60.03 | 62,253 |
| 2021-08-04 | Mainolfi Nello (Chief Executive Officer) | Option Ex | 1,037 | 2.08 | 2,156 |
| 2021-08-03 | Mainolfi Nello (Chief Executive Officer) | Sale | 5,669 | 60.07 | 340,531 |
| 2021-08-03 | Mainolfi Nello (Chief Executive Officer) | Option Ex | 5,669 | 2.08 | 11,791 |
| 2021-08-02 | Mainolfi Nello (Chief Executive Officer) | Sale | 23,456 | 61.23 | 1,436,210 |
| 2021-08-02 | Mainolfi Nello (Chief Executive Officer) | Option Ex | 23,456 | 2.08 | 48,788 |
| 2021-07-30 | Mainolfi Nello (Chief Executive Officer) | Sale | 6,279 | 60.07 | 377,166 |
| 2021-07-30 | Mainolfi Nello (Chief Executive Officer) | Option Ex | 6,279 | 2.08 | 13,060 |
| 2021-07-29 | Mainolfi Nello (Chief Executive Officer) | Sale | 680 | 60.00 | 40,800 |
| 2021-07-29 | Mainolfi Nello (Chief Executive Officer) | Option Ex | 680 | 2.08 | 1,414 |
| 2021-07-28 | Mainolfi Nello (Chief Executive Officer) | Sale | 3,864 | 60.15 | 232,408 |
| 2021-07-28 | Mainolfi Nello (Chief Executive Officer) | Option Ex | 3,864 | 2.08 | 8,037 |
| 2021-07-26 | Mainolfi Nello (Chief Executive Officer) | Sale | 9,015 | 60.15 | 542,234 |
| 2021-07-26 | Mainolfi Nello (Chief Executive Officer) | Option Ex | 9,015 | 2.08 | 18,751 |
| 2021-07-08 | Mainolfi Nello (Chief Executive Officer) | Sale | 48,000 | 50.37 | 2,417,520 |
| 2021-07-08 | Mainolfi Nello (Chief Executive Officer) | Option Ex | 48,000 | 2.08 | 99,840 |
| 2021-07-01 | Lampert Mark N | Buy | 544,166 | 47.00 | 25,575,802 |
| 2021-06-09 | Mainolfi Nello (Chief Executive Officer) | Sale | 5,752 | 50.02 | 287,720 |
| 2021-06-09 | Mainolfi Nello (Chief Executive Officer) | Option Ex | 5,752 | 2.08 | 11,964 |
| 2021-06-08 | Mainolfi Nello (Chief Executive Officer) | Sale | 270 | 50.00 | 13,500 |
| 2021-06-08 | Mainolfi Nello (Chief Executive Officer) | Option Ex | 270 | 2.08 | 561 |
| 2021-06-07 | Mainolfi Nello (Chief Executive Officer) | Sale | 12,724 | 50.15 | 638,044 |
| 2021-06-07 | Mainolfi Nello (Chief Executive Officer) | Option Ex | 12,724 | 2.08 | 26,465 |
| 2021-05-19 | Mainolfi Nello (Chief Executive Officer) | Option Ex | 15,000 | 2.08 | 31,200 |
| 2021-05-12 | Mainolfi Nello (Chief Executive Officer) | Sale | 8,245 | 50.05 | 412,678 |
| 2021-05-12 | Mainolfi Nello (Chief Executive Officer) | Option Ex | 8,245 | 2.08 | 17,149 |
| 2021-04-26 | Mainolfi Nello (Chief Executive Officer) | Sale | 2,768 | 40.18 | 111,229 |
| 2021-04-26 | Mainolfi Nello (Chief Executive Officer) | Option Ex | 2,768 | 2.08 | 5,757 |
| 2021-04-23 | Mainolfi Nello (Chief Executive Officer) | Sale | 680 | 40.01 | 27,207 |
| 2021-04-23 | Mainolfi Nello (Chief Executive Officer) | Option Ex | 680 | 2.08 | 1,414 |
| 2021-04-22 | Mainolfi Nello (Chief Executive Officer) | Sale | 10,959 | 40.26 | 441,187 |
| 2021-04-22 | Mainolfi Nello (Chief Executive Officer) | Option Ex | 10,959 | 2.08 | 22,794 |
| 2021-04-19 | Mainolfi Nello (Chief Executive Officer) | Sale | 653 | 40.00 | 26,120 |
| 2021-04-19 | Mainolfi Nello (Chief Executive Officer) | Option Ex | 6,653 | 2.08 | 13,838 |
| 2021-04-15 | Mainolfi Nello (Chief Executive Officer) | Sale | 4,940 | 40.29 | 199,037 |
| 2021-04-15 | Mainolfi Nello (Chief Executive Officer) | Option Ex | 4,940 | 2.08 | 10,275 |
| 2021-04-13 | Mainolfi Nello (Chief Executive Officer) | Option Ex | 15,000 | 2.08 | 31,200 |
| 2021-03-15 | Gollob Jared (Chief Medical Officer) | Sale | 10,305 | 60.17 | 620,051 |
| 2021-03-15 | Gollob Jared (Chief Medical Officer) | Option Ex | 7,800 | 1.31 | 10,218 |
| 2021-03-15 | Jacobs Bruce N. (Chief Financial Officer) | Sale | 8,195 | 60.17 | 493,093 |
| 2021-03-15 | Jacobs Bruce N. (Chief Financial Officer) | Option Ex | 8,195 | 2.08 | 17,045 |
| 2021-03-12 | Atlas Venture Associates X, Llc (10% Owner) | Sale | 229,350 | 56.50 | 12,958,275 |
| 2021-03-12 | Booth Bruce (Director) | Sale | 229,350 | 56.50 | 12,958,275 |
| 2021-03-11 | Gollob Jared (Chief Medical Officer) | Sale | 4,695 | 60.05 | 281,939 |
| 2021-03-11 | Gollob Jared (Chief Medical Officer) | Option Ex | 2,200 | 1.31 | 2,882 |
| 2021-03-11 | Jacobs Bruce N. (Chief Financial Officer) | Sale | 1,805 | 60.07 | 108,431 |
| 2021-03-11 | Jacobs Bruce N. (Chief Financial Officer) | Option Ex | 1,805 | 2.08 | 3,754 |
| 2021-03-08 | Jacobs Bruce N. (Chief Financial Officer) | Sale | 10,000 | 51.30 | 512,950 |
| 2021-03-08 | Jacobs Bruce N. (Chief Financial Officer) | Option Ex | 10,000 | 2.08 | 20,800 |
| 2021-03-03 | Jacobs Bruce N. (Chief Financial Officer) | Sale | 20,000 | 44.98 | 899,599 |
| 2021-03-03 | Jacobs Bruce N. (Chief Financial Officer) | Option Ex | 20,000 | 2.08 | 41,600 |
| 2021-02-24 | Gollob Jared (Chief Medical Officer) | Sale | 8,675 | 50.91 | 441,670 |
| 2021-02-23 | Gollob Jared (Chief Medical Officer) | Sale | 19,285 | 49.65 | 957,558 |
| 2021-02-22 | Gollob Jared (Chief Medical Officer) | Sale | 9,104 | 52.63 | 479,134 |
| 2021-02-19 | Gollob Jared (Chief Medical Officer) | Sale | 8,887 | 55.09 | 489,558 |
| 2021-02-18 | Gollob Jared (Chief Medical Officer) | Sale | 6,499 | 55.94 | 363,541 |
| 2021-02-17 | Gollob Jared (Chief Medical Officer) | Sale | 7,550 | 58.39 | 440,836 |
Insider trading activities including stock purchases, stock sales, and option exercises of KYMR listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Kymera Therapeutics, Inc. (symbol KYMR, CIK number 1815442) see the Securities and Exchange Commission (SEC) website.